AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26805505 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training (15 sessions over 5 weeks, 3 sessions per week)
Number of subjects: 16
Study 26805505 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 16
Study 22907731 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) treatment in blacks
Number of subjects: 0
Study 22907731 — intervention group
Group type: EXPERIMENTAL
Intervention: KCNJ1 variation in HCTZ-treated patients
Number of subjects: 0
Study 21394017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo technical skills training on low fidelity synthetic model
Number of subjects: 18
Study 21394017 — intervention group
Group type: COMPARATOR
Intervention: No further contact with the models (Control)
Number of subjects: 18
Study 18489017 — intervention group
Group type: EXPERIMENTAL
Intervention: therapist-delivered CRA treatment with vouchers
Number of subjects: 135
Study 18489017 — intervention group
Group type: EXPERIMENTAL
Intervention: computer-assisted CRA treatment with vouchers
Number of subjects: 135
Study 18489017 — intervention group
Group type: COMPARATOR
Intervention: standard treatment
Number of subjects: 135
Study 20576719 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/doxorubicin/cyclophosphamide
Number of subjects: 0
Study 20576719 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil/doxorubicin/cyclophosphamide
Number of subjects: 0
Study 16353054 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study 11865833 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF) 1800 mg daily
Number of subjects: 10
Study 11865833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9741018 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous corticotrophin (ACTH) 120 U/day
Number of subjects: 88
Study 9741018 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 300 mg/day
Number of subjects: 88
Study 8275731 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC), 40 mg/kg/d, intravenously for 3 days
Number of subjects: 61
Study 8275731 — intervention group
Group type: COMPARATOR
Intervention: Placebo, intravenously for 3 days
Number of subjects: 61
Study 2500462 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (2 mg intravenously)
Number of subjects: 0
Study 2500462 — intervention group
Group type: COMPARATOR
Intervention: Ro 15‐1788
Number of subjects: 0
Study 2500462 — intervention group
Group type: COMPARATOR
Intervention: Ro 15‐3505
Number of subjects: 0
Study 4816852 — intervention group
Group type: EXPERIMENTAL
Intervention: Stripping of the long saphenous vein upwards
Number of subjects: 30
Study 4816852 — intervention group
Group type: COMPARATOR
Intervention: Stripping of the long saphenous vein downwards
Number of subjects: 30
Study 30315436 — intervention group
Group type: EXPERIMENTAL
Intervention: SSMBI training
Number of subjects: 120
Study 30315436 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 120
Study 29957136 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatone supplement
Number of subjects: 9
Study 29957136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 27347996 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatinose™ (PSE)
Number of subjects: 20
Study 27347996 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (MDX)
Number of subjects: 20
Study 24304594 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine test
Number of subjects: 14
Study 24304594 — intervention group
Group type: COMPARATOR
Intervention: Water drinking test
Number of subjects: 14
Study 21639596 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.82 g/kg males; 0.74 g/kg females)
Number of subjects: 720
Study 21639596 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 720
Study 21639596 — intervention group
Group type: COMPARATOR
Intervention: No-alcohol control beverage
Number of subjects: 720
Study 19528265 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ceftazidime (200 mg/kg of body weight/day)
Number of subjects: 69
Study 19528265 — intervention group
Group type: COMPARATOR
Intervention: Short infusions of ceftazidime (200 mg/kg of body weight/day)
Number of subjects: 69
Study 19528265 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ceftazidime
Number of subjects: 69
Study 19528265 — intervention group
Group type: COMPARATOR
Intervention: Short infusions of ceftazidime
Number of subjects: 69
Study 19528265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 69
Study 17279435 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysate
Number of subjects: 63
Study 17279435 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone membrane after 1 year of HD
Number of subjects: 63
Study 17279435 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 63
Study 17279435 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from UFH to LMWH (n=4)
Number of subjects: 63
Study 17279435 — intervention group
Group type: COMPARATOR
Intervention: Continuation of UFH
Number of subjects: 63
Study 15301659 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement for 12-step involvement (ME-12)
Number of subjects: 48
Study 15301659 — intervention group
Group type: COMPARATOR
Intervention: Brief advice (BA) to attend Alcoholics Anonymous
Number of subjects: 48
Study 11154252 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient follow up study design for screening evaluation
Number of subjects: 0
Study 9581697 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 1022
Study 8160254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin and clavulanic acid
Number of subjects: 15
Study 3182964 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose calcitriol (≤ 0.50 micrograms/day)
Number of subjects: 30
Study 30082338 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health intervention involving formative research, culturally based performing arts, competitions, and environmental clues, implemented over four intensive days per village.
Number of subjects: 300
Study 30082338 — intervention group
Group type: COMPARATOR
Intervention: Public health intervention (details not specified)
Number of subjects: 300
Study 27172616 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-worn accelerometers
Number of subjects: 73
Study 27172616 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip-worn accelerometers
Number of subjects: 73
Study 25399621 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt cannula
Number of subjects: 20
Study 25399621 — intervention group
Group type: COMPARATOR
Intervention: Needle
Number of subjects: 20
Study 24341368 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored implementation program for practice nurses including training, feedback on motivational interviewing, e-learning on cardiovascular risk management, and advice on screening for depressive symptoms.
Number of subjects: 900
Study 24341368 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored implementation program for practice nurses.
Number of subjects: 900
Study 24341368 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by control practices.
Number of subjects: 900
Study 20720348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine plus L-carnitine
Number of subjects: 254
Study 20720348 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine
Number of subjects: 254
Study 19040806 — intervention group
Group type: EXPERIMENTAL
Intervention: Papacárie gel (chemomechanical caries removal agent)
Number of subjects: 51
Study 16368839 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating catheter with 0.125% levobupivacaine (group S-125)
Number of subjects: 48
Study 16368839 — intervention group
Group type: COMPARATOR
Intervention: Nonstimulating catheter with 0.125% levobupivacaine (group NS-125)
Number of subjects: 48
Study 16368839 — intervention group
Group type: COMPARATOR
Intervention: Stimulating catheter with 0.0625% levobupivacaine (group S-0625)
Number of subjects: 48
Study 12084589 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI within 24 hours of enrollment
Number of subjects: 9461
Study 12084589 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI at 24 to 72 hours
Number of subjects: 9461
Study 12084589 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI at 3 to 7 days
Number of subjects: 9461
Study 12084589 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI at 8 to 30 days
Number of subjects: 9461
Study 10426697 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress during the mental task
Number of subjects: 14
Study 10426697 — intervention group
Group type: COMPARATOR
Intervention: Control sessions (without mental stress)
Number of subjects: 14
Study 7559306 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourette's syndrome (TS)
Number of subjects: 71
Study 7559306 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic tic disorder
Number of subjects: 71
Study 7559306 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 71
Study 2191855 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 135
Study 2191855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 2191855 — intervention group
Group type: COMPARATOR
Intervention: Not treated with enalapril (control)
Number of subjects: 135
Study 343806 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate ointment
Number of subjects: 16
Study 343806 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 16
Study 31724424 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based weight loss intervention (n = 100)
Number of subjects: 194
Study 31724424 — intervention group
Group type: COMPARATOR
Intervention: Active control components (n = 94)
Number of subjects: 194
Study 28150436 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 94
Study 28150436 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 94
Study 28150436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 26267600 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 43
Study 24504761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 1500
Study 24504761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 23855170 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji VII (glass ionomer based)
Number of subjects: 50
Study 23855170 — intervention group
Group type: EXPERIMENTAL
Intervention: Admira Seal (ormocer based)
Number of subjects: 50
Study 23855170 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both sealants
Number of subjects: 50
Study 21175439 — intervention group
Group type: EXPERIMENTAL
Intervention: oseltamivir 75 mg twice daily for 4.5 days
Number of subjects: 20
Study 21175439 — intervention group
Group type: COMPARATOR
Intervention: warfarin alone
Number of subjects: 20
Study 21175439 — intervention group
Group type: EXPERIMENTAL
Intervention: oseltamivir + warfarin
Number of subjects: 20
Study 18723329 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin, Linezolid, Quinupristin/Dalfopristin, Semisynthetic lipoglycopeptides
Number of subjects: 0
Study 18723329 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem
Number of subjects: 0
Study 18723329 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxins
Number of subjects: 0
Study 18723329 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 0
Study 18723329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Number of subjects: 0
Study 18723329 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic lock therapy
Number of subjects: 0
Study 18723329 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous administration of antibiotics
Number of subjects: 0
Study 16640640 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA 17%
Number of subjects: 16
Study 16640640 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTAC 17%
Number of subjects: 16
Study 16640640 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid 10%
Number of subjects: 16
Study 14585939 — intervention group
Group type: EXPERIMENTAL
Intervention: ximelagatran (24 mg, taken twice daily for 18 months)
Number of subjects: 1233
Study 14585939 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1233
Study 10972907 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (300 microg filgrastim) given three times weekly for 12 weeks
Number of subjects: 30
Study 10972907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9526580 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (5 mg/kg) following PBPC infusion
Number of subjects: 26
Study 9526580 — intervention group
Group type: COMPARATOR
Intervention: Standard support care only
Number of subjects: 26
Study 8317948 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐deoxyglucose (2DG) 50 mg/kg
Number of subjects: 29
Study 8317948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 3555126 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 40
Study 3555126 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 40
Study 3555126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31692226 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (EXE) once weekly + dapagliflozin (DAPA) once daily
Number of subjects: 695
Study 31692226 — intervention group
Group type: COMPARATOR
Intervention: Exenatide (EXE) once weekly + placebo (PLB)
Number of subjects: 695
Study 31692226 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin (DAPA) + placebo (PLB)
Number of subjects: 695
Study 28550417 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) in addition to standard functional restoration program
Number of subjects: 728
Study 28550417 — intervention group
Group type: COMPARATOR
Intervention: Standard functional restoration program (control)
Number of subjects: 728
Study 28550417 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) adherence
Number of subjects: 728
Study 28550417 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployed claimants
Number of subjects: 728
Study 28550417 — intervention group
Group type: EXPERIMENTAL
Intervention: Employed claimants
Number of subjects: 728
Study 26535593 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40-80 mg daily
Number of subjects: 0
Study 26535593 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol 100-300 mg daily
Number of subjects: 0
Study 25490971 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of LHSs to build knowledge and skills, clinical mentorship, and written feedback to LHWs.
Number of subjects: 170
Study 25490971 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 170
Study 22749443 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM intervention (Program of Resources, Information and Support for Mothers)
Number of subjects: 0
Study 22749443 — intervention group
Group type: EXPERIMENTAL
Intervention: Document analysis
Number of subjects: 0
Study 20378235 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention (COMPASS) including a newly designed ward observation chart, a track and trigger system, and an associated education program
Number of subjects: 1157
Study 20378235 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention (COMPASS)
Number of subjects: 1157
Study 18206734 — intervention group
Group type: EXPERIMENTAL
Intervention: 1997 ADA IFG definition (fasting plasma glucose 110 to 125 mg/dl)
Number of subjects: 423
Study 18206734 — intervention group
Group type: EXPERIMENTAL
Intervention: 2003 ADA IFG definition (fasting plasma glucose 100 to 125 mg/dl)
Number of subjects: 423
Study 18206734 — intervention group
Group type: COMPARATOR
Intervention: Diabetes (as a comparison group)
Number of subjects: 423
Study 18206734 — intervention group
Group type: EXPERIMENTAL
Intervention: 1997 ADA IFG definition
Number of subjects: 423
Study 18206734 — intervention group
Group type: EXPERIMENTAL
Intervention: 2003 ADA IFG definition
Number of subjects: 423
Study 15870317 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard formula supplemented with galacto‐ and fructo‐oligosaccharides (OSF)
Number of subjects: 0
Study 15870317 — intervention group
Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 0
Study 12087953 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone prophylaxis
Number of subjects: 70
Study 12087953 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoroquinolone prophylaxis)
Number of subjects: 70
Study 14518329 — intervention group
Group type: EXPERIMENTAL
Intervention: J pouch anastomosis
Number of subjects: 40
Study 14518329 — intervention group
Group type: COMPARATOR
Intervention: Coloanal reconstruction
Number of subjects: 40
Study 7986706 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin‐3 (IL‐3) at 10 micrograms/kg/d
Number of subjects: 27
Study 7986706 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin‐3 (IL‐3) at 15 micrograms/kg/d
Number of subjects: 27
Study 7986706 — intervention group
Group type: COMPARATOR
Intervention: Control (ICE chemotherapy without IL‐3)
Number of subjects: 27
Study 2525397 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with medroxyprogesterone acetate at high dosage (HD‐MPA; 500 mg IM per day times 28 or 500 mg i.m. 5 days a week for 5 weeks then 500 mg i.m. twice weekly for the 5 following months
Number of subjects: 240
Study 2525397 — intervention group
Group type: COMPARATOR
Intervention: No hormone therapy
Number of subjects: 240
Study 4883651 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive with low oestrogen/progestogen content
Number of subjects: 20
Study 4883651 — intervention group
Group type: COMPARATOR
Intervention: Identical dummy tablets (control)
Number of subjects: 20
Study 107450 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg
Number of subjects: 1080
Study 107450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1080
Study 107450 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 1080
Study 31172823 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training protocol with incremental loading (50%, 60%, and 70% of MIP) for 12 weeks
Number of subjects: 17
Study 31172823 — intervention group
Group type: COMPARATOR
Intervention: Control group performed with load 15% of MIP
Number of subjects: 17
Study 31727410 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg prednisolone
Number of subjects: 92
Study 31727410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 28752693 — intervention group
Group type: EXPERIMENTAL
Intervention: Human bone mineral allograft (freeze-dried bone allograft, FDBA)
Number of subjects: 13
Study 28752693 — intervention group
Group type: COMPARATOR
Intervention: Biphasic calcium phosphate (BCP) alloplastic bone substitute
Number of subjects: 13
Study 26382217 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 177
Study 23323877 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 334
Study 23323877 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 334
Study 23323877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 21290116 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring autograft (group I)
Number of subjects: 106
Study 21290116 — intervention group
Group type: EXPERIMENTAL
Intervention: Achilles allograft (group II)
Number of subjects: 106
Study 19556318 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin 1.5 mg/m2 24 h (arm A)
Number of subjects: 107
Study 19556318 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin 1.3 mg/m2 3 h (arm B)
Number of subjects: 107
Study 17373190 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% oleic acid emulsion before phototherapy
Number of subjects: 44
Study 17373190 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy without emulsion
Number of subjects: 44
Study 14718678 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa combined with COMT inhibitor entacapone
Number of subjects: 0
Study 14718678 — intervention group
Group type: COMPARATOR
Intervention: Levodopa alone
Number of subjects: 0
Study 14718678 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa combined with entacapone
Number of subjects: 0
Study 11239866 — intervention group
Group type: EXPERIMENTAL
Intervention: unoprostone isopropyl 0.12%
Number of subjects: 41
Study 11239866 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study 9885092 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention consisting of 35 weekly, 2 h sessions of supportive plus cognitive behavioral therapy; n = 30
Number of subjects: 66
Study 9885092 — intervention group
Group type: COMPARATOR
Intervention: Control group received only a home study cognitive behavioral package; n = 36
Number of subjects: 66
Study 9885092 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported exercise
Number of subjects: 66
Study 9885092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention subjects who attended outside support groups
Number of subjects: 66
Study 7987430 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal function exercises
Number of subjects: 35
Study 7987430 — intervention group
Group type: COMPARATOR
Intervention: Placebo exercise program
Number of subjects: 35
Study 7987430 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 2691402 — intervention group
Group type: EXPERIMENTAL
Intervention: Test toothpaste with 550 ppm fluoride
Number of subjects: 3000
Study 2691402 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste with 1055 ppm fluoride
Number of subjects: 3000
Study 30864473 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge analgesia prescribing compliance
Number of subjects: 100